This is a phase I, open label, dose escalation trial to assess the safety and immunogenicity of the ChAdOx1 Chik vaccine in healthy volunteers~There will be 3 study groups with a total of 24 volunteers. ChAdOx1 Chik will be administered intramuscularly as a single vaccination at 3 different doses: 5x10^9 vp (group 1), 2.5x10^10 (group 2) and 5x10^10 vp (group 3)~Vaccination of groups will be sequential from Group 1 to Group 3 with interim safety reviews prior to dose escalation~Volunteers will be recruited and undergo screening, vaccination and follow-up visits at the trial site. Blood samples for safety and immunology purposes will be performed on the visit time points indicated in the schedule of attendances.~Safety will be assessed by the frequency, incidence and nature of adverse events and serious adverse events arising during the study.~Immune responses will be assessed pre and post vaccination procedure at different time points throughout the trial
A phase I dose escalation study to assess the safety and immunogenicity of the candidate vaccine ChAdOx1 Chik in healthy volunteers.~Volunteers will be recruited and vaccinated in Oxford, England.~All vaccinations will be administered intramuscularly. Three different doses will be tested (5x10^9 vp, 2.5x10^10 vp and 5x10^10vp).~The total duration of the study will be 26 weeks from the day of enrolment for all volunteers.